2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk. 
Masks are optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details. 

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 23095

USO 23095

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003)

 

Disease Types: Lung Cancer Research

Eligibility Requirements:

- Age > 18 years old at the time of enrollmen

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Expected life expectancy > 3 months

- Metastatic (Stage IV) NSCLC

- Histologically or cytologically confirmed squamous NSCLC

- Tumor Proportion Score (TPS) with PD-L1 expression percent

- At least one measurable noncerebral lesion according to RECIST 1.1

- No prior systemic treatment for metastatic NSCLC

Available at:

Virginia Oncology Associates